Targeting GM-CSF in COVID-19 pneumonia: rationale and strategies
A Bonaventura, A Vecchié, TS Wang, E Lee… - Frontiers in …, 2020 - frontiersin.org
COVID-19 is a clinical syndrome ranging from mild symptoms to severe pneumonia that
often leads to respiratory failure, need for mechanical ventilation, and death. Most of the lung …
often leads to respiratory failure, need for mechanical ventilation, and death. Most of the lung …
IL‐18 and infections: Is there a role for targeted therapies?
A Vecchie, A Bonaventura, S Toldo… - Journal of cellular …, 2021 - Wiley Online Library
Abstract Interleukin (IL)‐18 is a pro‐inflammatory cytokine belonging to the IL‐1 family, first
identified for its interferon‐γ‐inducing properties. IL‐18 regulates both T helper (Th) 1 and …
identified for its interferon‐γ‐inducing properties. IL‐18 regulates both T helper (Th) 1 and …
“Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French …
A Gérard, S Romani, A Fresse, D Viard, N Parassol… - Therapies, 2020 - Elsevier
Introduction COVID-19 is an unprecedented challenge for physicians and scientists. Several
publicized drugs are being used with not much evidence of their efficacy such as …
publicized drugs are being used with not much evidence of their efficacy such as …
Weathering the cytokine storm in COVID-19: therapeutic implications
G Iannaccone, R Scacciavillani, MG Del Buono… - Cardiorenal …, 2020 - karger.com
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recently
emerged in Wuhan, Hubei-China, as responsible for the coronavirus disease 2019 (COVID …
emerged in Wuhan, Hubei-China, as responsible for the coronavirus disease 2019 (COVID …
Systemic mycoses: a potential alert for complications in COVID-19 patients
G Segrelles-Calvo, GR de S Araujo… - Future Microbiology, 2020 - Taylor & Francis
As the global COVID-19 pandemic spreads worldwide, new challenges arise in the clinical
landscape. The need for reliable diagnostic methods, treatments and vaccines for COVID-19 …
landscape. The need for reliable diagnostic methods, treatments and vaccines for COVID-19 …
Cardiovascular complications of COVID-19: pharmacotherapy perspective
Abstract Coronavirus disease of 2019 (COVID-19), which is caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly the world over. The …
respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly the world over. The …
Pathogenic pathways and therapeutic targets of inflammation in heart diseases: A focus on Interleukin‐1
MG Del Buono, A Bonaventura… - European Journal of …, 2024 - Wiley Online Library
Background An exuberant and dysregulated inflammatory response contributes to the
development and progression of cardiovascular diseases (CVDs). Methods This narrative …
development and progression of cardiovascular diseases (CVDs). Methods This narrative …
Cardiopulmonary exercise testing during the COVID-19 pandemic
The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection has presented a global public health emergency. Although predominantly a …
infection has presented a global public health emergency. Although predominantly a …
The potential impact of COVID-19 virus on the heart and the circulatory system
MS Alqahtani, M Abbas, A Alsabaani… - Infection and Drug …, 2022 - Taylor & Francis
Heart attacks, arrhythmias, and cardiomyopathy are all linked to the 2019 coronavirus
disease (COVID-19), which has been identified as a risk factor for cardiovascular disease …
disease (COVID-19), which has been identified as a risk factor for cardiovascular disease …
Is sex a determinant of COVID-19 infection? Truth or myth?
Abstract Purpose of Review Angiotensin-converting enzyme 2 (ACE2), a specific high-
affinity angiotensin II-hydrolytic enzyme, is the vector that facilitates cellular entry of SARS …
affinity angiotensin II-hydrolytic enzyme, is the vector that facilitates cellular entry of SARS …